Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Hutchmed Share Price
  4. Hutchmed Share Regulatory News

Pin to quick picksHutchmed Regulatory News (HCM)

Hutchmed Information

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
161.50    -11.00 (-6.38%)
Bid:
158.50
Ask:
162.50
Spread: 4.00 (2.524%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

12345678910
Date   Source Headline
30th Jun 20259:30 amRNSTotal Voting Rights
30th Jun 20259:30 amRNSBlocklisting Six Monthly Return
10th Jun 202511:00 amRNSGrant of Share Options and Awards under LTIP
5th Jun 20257:00 amRNS-RHUTCHMED and Innovent Announce NDA Acceptance
2nd Jun 20257:00 amRNS-RHUTCHMED Highlights SACHI Phase III Data at ASCO
30th May 20259:30 amRNSTotal Voting Rights
23rd May 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at ASCO
13th May 202511:45 amRNSAGM held on May 13, 2025 – Poll Results
24th Apr 20257:00 amRNS-RHUTCHMED - Data to be Presented at AACR 2025
22nd Apr 20257:00 amRNS-RHUTCHMED Completes Enrollment of Phase II Study
7th Apr 20259:30 amRNS2024 Annual Report and Notice of AGM
31st Mar 202510:30 amRNSExtraordinary General Meeting – Poll Results
21st Mar 202510:00 amRNS-RNMPA Conditional Approval for TAZVERIK®
20th Mar 20259:30 amRNSRetirement of Independent Non-executive Directors
20th Mar 20257:00 amRNS-RHUTCHMED Highlights Savolitinib SAVANNAH Phase II
19th Mar 20251:45 pmRNS-RPublication of Form 20-F
19th Mar 202511:00 amRNS2024 Final Results and Business Updates
19th Mar 20257:00 amRNS-RPhase II/III Study of Fruquintinib and Sintilimab
14th Mar 20259:30 amRNSAdoption of the 2025 Long Term Incentive Plan
14th Mar 20259:30 amRNSVesting of awards under Long Term Incentive Plan
13th Mar 20259:30 amRNSNotice of Extraordinary General Meeting
6th Mar 202510:00 amRNS-RCompleted Enrollment of Phase II Study
5th Mar 202510:00 amRNSDirectorate Change
3rd Mar 20257:00 amRNSOverseas Regulatory Announcement
28th Feb 20253:00 pmRNSOverseas Regulatory Announcement
19th Feb 20258:30 amRNSNotice of Results
28th Jan 20259:00 amRNSOverseas Regulatory Announcement
14th Jan 20257:00 amRNS-RFull Approval for ORPATHYS in China
2nd Jan 20257:00 amRNSOverseas Regulatory Announcement
2nd Jan 20257:00 amRNSUS$608m Divestment of Non-Core Joint Venture
31st Dec 20248:30 amRNSAppointment of Joint Corporate Broker
30th Dec 20248:30 amRNSBlocklisting Six Monthly Return
29th Nov 20248:30 amRNSTotal Voting Rights
20th Nov 20249:30 amRNSAppointment of Independent Non-executive Director
31st Oct 20248:30 amRNSTotal Voting Rights
21st Oct 20249:30 amRNSVesting of awards under the LTIP
16th Oct 20247:00 amRNSSAVANNAH: clinically meaningful response rate
24th Sep 20248:00 amRNSJapan Approval for FRUZAQLA
30th Aug 20249:30 amRNSTotal Voting Rights
30th Aug 20247:00 amRNSUpdate on Fruquintinib for Gastric Cancer in China
22nd Aug 20249:30 amRNSStandard form for notification of major holdings
6th Aug 202410:00 amRNSLTIP and Share Option Scheme
31st Jul 202412:00 pmRNS2024 Interim Results and Business Updates
28th Jun 20249:30 amRNSTotal Voting Rights
28th Jun 20249:30 amRNSBlocklisting Six Monthly Return
26th Jun 20249:30 amRNSHUTCHMED to Announce 2024 HY Financial Results
24th Jun 20247:00 amRNSEuropean Commission Approval for FRUZAQLA
7th Jun 20247:00 amRNSHUTCHMED Initiates Phase I Trial of HMPL-506
3rd Jun 20247:00 amRNSNature Medicine Publish Phase III FRUTIGA Results
31st May 20249:30 amRNSTotal Voting Rights
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
RDI
RDI.L
LSE
0.00%
GFM
Griffin Mining
LSE
-0.62%
CWC
CWC.L
LSE
0.00%
DFI
Dfi Retail Intl
LSE
0.00%
PDL
Petra Diamonds
LSE
-7.37%
Trending
AVCT
Avacta Group
LSE
2.14%
ALRT
Defence Holdings
LSE
19.05%
ITM
Itm Power
LSE
-10.85%
NANO
Nanoco
LSE
-10.69%
FORG
Forgent
LSE
26.67%